BioSpace’s Post

SPECIAL REPORT: GROWING TENSIONS BETWEEN U.S. AND CHINA IMPACT BIOPHARMA INDUSTRY AS BIOSECURE ACT ADVANCES US-China Tensions Deepen, Impacting Biopharma Sector The U.S. biopharma industry is facing significant challenges as geopolitical tensions with China intensify. The BIOSECURE Act, a bipartisan bill introduced by Reps. Mike Gallagher (R-Wis.) and Raja Krishnamoorthi (D-Ill.) in January 2024, is designed to prevent the flow of taxpayer dollars to biotech entities controlled by foreign adversaries. The legislation targets several Chinese biotechs, including WuXi AppTec, WuXi Biologics, Beijing Genomics Institute, Complete Genomics, and MGI. KEY PROVISIONS OF THE BIOSECURE ACT The updated draft of the BIOSECURE Act, introduced earlier this month, sets a deadline of 2032 for U.S. drug manufacturers to sever ties with these Chinese biotech companies. The bill prohibits U.S. firms from entering new agreements or renewing existing contracts with these entities and includes a grandfather clause allowing current contracts to continue until January 1, 2032. Reps. Gallagher and Krishnamoorthi have emphasized that these companies “amass and analyze large amounts” of genomic data, posing a potential national security threat. Krishnamoorthi highlighted the risks, stating that adversarial governments could use this data against the U.S. To learn more about the BIOSECURE Act Read the rest of our report here: https://lnkd.in/dXrqkUbX #EuroAmericanRelations #BiosecureAct #BiotechInnovation #GlobalBiosecurity

🌐💼 Trade rivalry between the US & China spills over into Biotech 🔬 But amidst the tensions, collaboration remains the key🔑! We're all aiming for the same goals, and they are more important than frictions between any countries. New legislation aims to block 🚫 Chinese biopharma firms, including giants like WuXi AppTec and WuXi Biologics, from accessing US federal funding, causing market turbulence. The bill also specifically targets Chinese genomics firms like BGI Group, MGI, and Complete Genomics. Despite these challenges, companies like WuXi stand resilient, emphasizing their commitment to global compliance standards and contribution to the pharmaceutical and life sciences industries worldwide. And they're proving it! 💪 WuXi XDC recently secured a significant antibody-drug conjugate pact with South Korea's Celltrion Inc, showcasing the industry's resilience and capacity for innovation.💡 Similarly, companies like Samsung Biologics and Lonza have demonstrated remarkable performance, achieving record revenue.🌍 Despite the obstacles, the biotech industry is driving towards a brighter future. 🤝 What are your thoughts on the importance of collaboration in biotech despite global tensions? 💬 Share your insights in the comments below! #BiotechCollaboration #USChinaTrade #GlobalInnovation 🚀

🔬🇺🇦 Ukraine was once the burgeoning hub for clinical trials in the pharmaceutical industry. As the war persists, the impact on the sector has been severe, with trials significantly reduced from pre-war levels. What does the future hold for clinical trials in Ukraine? Read more about the ongoing situation and its effects on the industry.

This case is rightly raising questions and concerns. ➡️While we can’t say whether a conflict of interest exists here, the questions raised warrant a thorough investigation by the Advisory Committee on the Code of Conduct of Members. 🔎And this case provides us with yet more evidence (as if we ever needed it!) of the need for an independent EU ethics body, with the power to investigate potential conflicts of interest proactively. The current rules in place in the European Parliament to prevent conflicts of interest among MEPs are woefully inadequate - as this case highlights.

Disruptions in global pharma supply chains during the pandemic showcased the industry's reliance on China for not only outsourced manufacturing activities but also for key starting materials and APIs at the very top of the pharma supply chain. The unhealthy reliance on China was met by an industry consensus to prioritize supply chain resilience to de-risk and mitigate global supply chain failures in the midst of black swan events. Are we again, on the precipice of another serious global pharmaceutical supply chain disruption? As the US cracks down on China through the BioSecure Act, this should be seen as a wake up call to the wider industry to refocus their attentions on supply chain diversification.

Rapid regulatory processes in countries like Japan and China are fuelling clinical trial growth in APAC. The reforms in these countries ensure faster and more efficient approvals for innovative ventures. Learn more in this article: https://lnkd.in/gpyVXg7y #RegulatoryReforms #HiROUpdates #JapanTrials #ChinaResearch #BiotechReforms

Thoughts on this? >> China biotech ban does not make the cut as add-on to defense spending bill >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech

I'm interested in getting thoughts and opinions on this.

In light of the recent China Development Forum with many big Pharma CEOs in attendance, what do people make of the on-going China<>US issues in relation to healthcare? Do you think the big push on China from these CEOs will have an impact to counter the Biosecure Act? Let me know your thoughts in the comments.

Internet | China Biotech - Eric Wen At the time of our initiation of Akeso on October 2022, it only had six months of cash left but had a strong pipeline and a proven license-out track record. Since then, Akeso has turned profitable without resorting to external financing. Now, with the China’s innovative drug reform (2018) and the inflow of overseas returnees running their courses, liquidity crises again stroke the innovative drug sector and the medical device sector. However, we believe companies with quality pipelines should be able to mitigate their liquidity crises. We believe there are several companies undergoing liquidity crunches but with strong pipelines, including Ascentage and LEPU. Ascentage is China’s small molecule leader with nine drugs in clinical, one of which in Phase III, five in Phase II and one already selling. LEPU is a leading ADC platform with three ADC’s in Phase III, one of which was licenced to AstraZeneca. Read full story here: https://buff.ly/3xNMFnS For more information on our #internet product, and other Aletheia Capital research, please contact info@aletheia-capital.com #investments #advisory #ideas #fintech #InYourCorner